Answers are grounded in this paper and cite their sources.
Invasive lobular carcinoma (ILC) is the 2nd most common histological breast cancer (BC) subtype, with distinctive clinical-biological features. In patients (pts) with Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative advanced BC (HR+/HER2- aBC), pivotal trials showed that the Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i) palbociclib (P), ribociclib (R) and abemaciclib (A) are effective in ILC. However, the real-world (RW) effectiveness of the three CDK4/6i in ILC pts remains unexplored.
No takes yet. Share an insight, caveat, or question.
Vernieri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: